USA - engelsk - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. the use of levocetirizine dihydrochloride tablets is contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablets, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2)] . patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis. children 6 months to 11 years of age with impaired renal function. risk summary available data from published literature and postmarketing experience with levocetirizine use in pregnant women are insufficient to identify any drug-associated risks of miscarriage, birth defects, or adverse maternal or fetal outcomes. in animal reproduction studies, there was no evidence of fetal harm with administration of levocetirizine by the ora

USA - engelsk - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older.   pediatric use information in pediatric patients (age 6 months to 5 years) is approved for ucb inc.’s levocetirizine dihydrochloride drug product labeling. however, due to ucb inc.’s marketing exclusivity rights; this drug product is not labeled for such use in those pediatric patients. the use of levocetirizine dihydrochloride tablet is contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablet, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2)]. patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis. children 6 months to 11 years of age with impaired renal function pregnancy category b   there are no adequate and well-controlled studies i

USA - engelsk - NLM (National Library of Medicine)

dispensing solutions, inc. - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. pediatric use information in pediatric patients (age 6 months to 5 years) is approved for ucb inc.'s levocetirizine dihydrochloride drug product labeling. however, due to ucb inc.'s marketing exclusivity rights; this drug product is not labeled for such use in those pediatric patients. the use of levocetirizine dihydrochloride tablets is contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablets, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions ( 6.2) ]. patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis. children 6 months to 11 years of age with impaired renal function. pregnancy category b there are no adequate and well-controlled studies in preg

Kenya - engelsk - Pharmacy and Poisons Board

finecure pharmaceuticals ltd village shimla pistaur, malsa rd kichha udha m - montelukast sodium and levocetirizine… - film-coated tablet - montelukast 10mg and levocetirizine 5mg - montelukast combinations

Malaysia - engelsk - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glaxosmithkline pharmaceutical sdn. bhd. - levocetirizine dihydrochloride -

Irland - engelsk - HPRA (Health Products Regulatory Authority)

krka pharma dublin limited - levocetirizine dihydrochloride - film coated tablet - 5 milligram

USA - engelsk - NLM (National Library of Medicine)

bryant ranch prepack - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. the use of levocetirizine dihydrochloride is contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablets, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2) ]. patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis. children 6 months to 11 years of age with impaired renal function. risk summary available data from published literature and postmarketing experience with levocetirizine use in pregnant women are insufficient to identify any drug-associated risks of miscarriage, birth defects, or adverse maternal or fetal outcomes. in animal reproduction studies, there was no evidence of fetal harm with administration of levocetirizine by the oral r

Malaysia - engelsk - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

stadpharm sdn. bhd. - levocetirizine dihydrochloride -

Kenya - engelsk - Pharmacy and Poisons Board

İlko İlaç san. ve tic. a.Ş. veysel karani mah. Çolakoğlu sk. no:10 34885 - levocetirizine dihydrochloride - film-coated tablet - 5 mg levocetirizine dihydrochloride - antihistamines for systemic use: piperazine

Irland - engelsk - HPRA (Health Products Regulatory Authority)

g & a licensing limited - levocetirizine dihydrochloride - film coated tablet - 5 milligram